353 related articles for article (PubMed ID: 18824337)
21. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
[TBL] [Abstract][Full Text] [Related]
22. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
Vincent-Salomon A; Pierga JY; Couturier J; d'Enghien CD; Nos C; Sigal-Zafrani B; Lae M; Fréneaux P; Diéras V; Thiéry JP; Sastre-Garau X
Br J Cancer; 2007 Feb; 96(4):654-9. PubMed ID: 17262082
[TBL] [Abstract][Full Text] [Related]
23. Receptor status and ethnicity of indigent patients with breast cancer in New York City.
Marti JL; Guth A; Naik A; Hiotis KL
Arch Surg; 2008 Dec; 143(12):1227-30. PubMed ID: 19075177
[TBL] [Abstract][Full Text] [Related]
24. Angiogenesis in the bone marrow of patients with breast cancer.
Chavez-Macgregor M; Aviles-Salas A; Green D; Fuentes-Alburo A; Gómez-Ruiz C; Aguayo A
Clin Cancer Res; 2005 Aug; 11(15):5396-400. PubMed ID: 16061853
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer diagnosis following ovarian stimulation: are the tumours different?
Sönmezer M; Cil AP; Oktem O; Oktay K
Reprod Biomed Online; 2010 Aug; 21(2):266-71. PubMed ID: 20615755
[TBL] [Abstract][Full Text] [Related]
26. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.
Kasami M; Uematsu T; Honda M; Yabuzaki T; Sanuki J; Uchida Y; Sugimura H
Breast; 2008 Oct; 17(5):523-7. PubMed ID: 18534850
[TBL] [Abstract][Full Text] [Related]
27. Estrogen and progesterone receptor status in primary breast cancer--a study of 11,273 patients from the year 1990 to 2002.
Vrbanec D; Petricević B
Coll Antropol; 2007 Jun; 31(2):535-40. PubMed ID: 17847935
[TBL] [Abstract][Full Text] [Related]
28. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
[TBL] [Abstract][Full Text] [Related]
29. Biomarker discordance between primary breast cancer and bone or bone marrow metastases.
Yuda S; Shimizu C; Yoshida M; Shiino S; Kinoshita T; Maeshima AM; Tamura K
Jpn J Clin Oncol; 2019 May; 49(5):426-430. PubMed ID: 30793198
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
Miglietta L; Vanella P; Canobbio L; Parodi MA; Guglielmini P; Boccardo F
Anticancer Res; 2009 May; 29(5):1621-5. PubMed ID: 19443376
[TBL] [Abstract][Full Text] [Related]
31. Quality indicators for the care of breast cancer in vulnerable elders.
Naeim A; Sawhney R; MacLean CH; Sanati H
J Am Geriatr Soc; 2007 Oct; 55 Suppl 2():S258-69. PubMed ID: 17910546
[No Abstract] [Full Text] [Related]
32. [A study on the relationship between breast cancer molecular classification and prognosis].
Chen XS; Ma CD; Chen CM
Zhonghua Wai Ke Za Zhi; 2008 Sep; 46(18):1400-3. PubMed ID: 19094512
[TBL] [Abstract][Full Text] [Related]
33. A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines.
Schiavon G; Tait DM; Briggs TW; Smith IE
Clin Breast Cancer; 2013 Feb; 13(1):77-80. PubMed ID: 23199805
[No Abstract] [Full Text] [Related]
34. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
[TBL] [Abstract][Full Text] [Related]
35. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
36. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
37. Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy.
Timmer M; Werner JM; Röhn G; Ortmann M; Blau T; Cramer C; Stavrinou P; Krischek B; Mallman P; Goldbrunner R
Anticancer Res; 2017 Sep; 37(9):4859-4865. PubMed ID: 28870906
[TBL] [Abstract][Full Text] [Related]
38. Oestrogen and progesterone receptor status of individual foci in multifocal invasive ductal breast cancer.
Garimella V; Long ED; O'Kane SL; Drew PJ; Cawkwell L
Acta Oncol; 2007; 46(2):204-7. PubMed ID: 17453370
[TBL] [Abstract][Full Text] [Related]
39. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.
Kok M; Koornstra RH; Margarido TC; Fles R; Armstrong NJ; Linn SC; Van't Veer LJ; Weigelt B
J Pathol; 2009 Jul; 218(3):316-26. PubMed ID: 19353633
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for skeletal relapse in breast cancer.
Diel IJ
Cancer Treat Rev; 2001 Jun; 27(3):153-7; discussion 159-64. PubMed ID: 11417965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
